文献速递产科母胎医学

双胎妊娠中基于早孕期联合筛查结果的无创产前检测用于胎儿三体常规筛查

Routine first-trimester screening for fetal trisomies in twin pregnancy: cell-free DNA test contingent on results from combined test.
PubMed 文献 · Ultrasound Obstet Gynecol · 2018-12-07

在959例双胎妊娠中,于孕11-13周行联合筛查,高风险组(风险≥1/100)可选侵入性检查、cfDNA检测或不进一步检测,中间风险组可选cfDNA或不进一步检测。214例获得cfDNA结果,全部6例21三体及3例18三体中的2例被正确判为筛查阳性,206例无三体妊娠均判为阴性;序贯筛查产前检出全部21三体及4例18三体中的3例。

要点

  • 双胎妊娠早孕期联合筛查后,高风险组可选cfDNA检测替代侵入性检查。
  • cfDNA检测在214例中提供结果,检出全部6例21三体和3例18三体中的2例。
  • 序贯筛查产前检出全部21三体及4例18三体中的3例。

核心结论

  • 在双胎妊娠常规人群中引入基于早孕期联合筛查结果的cfDNA检测是可行的。

研究设计与样本

  • 在英国两家NHS医院对959例双胎妊娠于孕11-13周行联合筛查(母亲年龄、胎儿颈项透明层厚度、血清游离β-hCG和妊娠相关血浆蛋白-A)。
  • 高风险组(风险≥1/100)可选侵入性检查、cfDNA检测或不进一步检测;中间风险组(第一阶段风险1/101至1/2500,第二阶段1/101至1/500)可选cfDNA或不进一步检测。
  • 妊娠三体状态通过产前或产后核型分析或新生儿检查确定。

主要发现

  • 959例中42例(4.4%)因终止妊娠、流产或死胎无已知核型或失访,917例双胎三体状态已知。
  • 917例中6例为21三体不一致,4例为18三体不一致,907例无21、18、13三体。
  • 联合筛查后高风险47例(5.1%)、中间风险203例(22.1%)、低风险667例(72.7%)。
  • 高风险组包含5例(83.3%)21三体和3例(75.0%)18三体。
  • cfDNA检测在224例中实施,214例(95.5%)获得结果,其中6例21三体、3例18三体和206例无三体;cfDNA正确判为筛查阳性全部6例21三体和3例18三体中的2例,206例无三体妊娠均判为阴性。

关键数值与推荐

  • 高风险组风险阈值为≥1/100。
  • 中间风险组第一阶段风险范围1/101至1/2500,第二阶段1/101至1/500。
  • 序贯筛查产前检出全部21三体及4例18三体中的3例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 959例中42例(4.4%)因终止妊娠、流产或死胎无已知核型或失访,无法确定三体状态。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To report on the routine clinical implementation of cell-free DNA (cfDNA) analysis of maternal blood for trisomies 21, 18 and 13, contingent on the results of the first-trimester combined test in twin pregnancy. METHODS: Screening for trisomies 21, 18 and 13 was carried out in 959 twin pregnancies by assessment of a combination of maternal age, fetal nuchal translucency thickness, and serum free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A at 11-13 weeks' gestation in two UK NHS hospitals. Women in the high-risk group (risk ≥ 1 in 100) were offered the option of invasive testing, cfDNA testing or no further testing, and those in the intermediate-risk group (risk 1 in 101 to 1 in 2500 in the first phase of the study and 1 in 101 to 1 in 500 in the second phase) were offered cfDNA or no further testing. The trisomic status of the pregnancies was determined by prenatal or postnatal karyotyping or examination of the neonates. RESULTS: In 42 (4.4%) of the 959 pregnancies, there was termination, miscarriage or stillbirth with no known karyotype or there was loss to follow-up. The 917 pregnancies with known trisomic status of both twins included six that were discordant for trisomy 21, four that were discordant for trisomy 18 and 907 with no trisomy 21, 18 or 13. Following combined screening, 47 (5.1%), 203 (22.1%) and 667 (72.7%) of the pregnancies were classified as high risk, intermediate risk and low risk, respectively. The high-risk group included five (83.3%) cases of trisomy 21 and three (75.0%) of trisomy 18. The cfDNA test was carried out in 224 pregnancies and results were provided in 214 (95.5%); this group included six pregnancies with trisomy 21, three with trisomy 18 and 206 with no trisomy 21, 18 or 13. The cfDNA test classified correctly as screen positive all six cases of trisomy 21 and two of the three with trisomy 18, and as screen negative for each of the trisomies all 206 unaffected pregnancies. Contingent screening led to prenatal detection of all cases of trisomy 21 and three of four with trisomy 18. CONCLUSION: This study has demonstrated the feasibility of introducing cfDNA testing, contingent on the results of the first-trimester combined test for major trisomies, in a routine population of twin pregnancies. Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Galeva S, Konstantinidou L, Gil MM, et al. Routine first-trimester screening for fetal trisomies in twin pregnancy: cell-free DNA test contingent on results from combined test. Ultrasound Obstet Gynecol. 2018. PMID: 30353581. doi:10.1002/uog.20160

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。